In contrast, and compared with other antibodies associated with SCLC and PNS (Hu or CRMP5), the frequency of patients with the final diagnosis of PNS was lower (87%) emphasizing the need to rule out alternative diagnoses for the neurological symptoms that may lead to antibody testing even when the presence of cancer is confirmed. The gene discussed is DPYSL5; the disease is paraneoplastic neurologic syndrome.